AU Stock MarketDetailed Quotes

TLX Telix Pharmaceuticals Ltd

Watchlist
  • 24.530
  • +0.420+1.74%
20min DelayMarket Closed Dec 13 16:00 AET
8.21BMarket Cap1533.13P/E (Static)

Telix Pharmaceuticals Ltd Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(FY)Dec 30, 2023
(FY)Dec 30, 2022
(FY)Dec 30, 2021
(FY)Dec 30, 2020
(FY)Dec 30, 2019
(FY)Dec 30, 2018
(FY)Dec 30, 2017
(FY)Sep 30, 2000
(FY)Sep 30, 1999
Total revenue
218.40%496.66M
3,084.65%155.98M
4.66%4.9M
34.29%4.68M
1,685.88%3.49M
195.14K
Operating revenue
218.40%496.66M
3,084.65%155.98M
4.66%4.9M
34.29%4.68M
1,685.88%3.49M
--195.14K
----
----
----
Cost of revenue
205.67%188.16M
2,315.86%61.56M
25.89%2.55M
-20.41%2.02M
2.54M
Gross profit
226.71%308.5M
3,918.21%94.43M
-11.52%2.35M
181.95%2.66M
382.73%942K
195.14K
Operating expense
42.13%269.27M
87.29%189.44M
92.88%101.15M
27.29%52.44M
47.93%41.2M
326.93%27.85M
6.52M
Selling and administrative expenses
43.15%133.85M
129.12%93.5M
112.46%40.81M
65.77%19.21M
27.64%11.59M
239.83%9.08M
--2.67M
----
----
-Selling and marketing expense
238.96%54.87M
174.78%16.19M
390.10%5.89M
285.26%1.2M
-46.02%312K
--577.95K
----
----
----
-General and administrative expense
2.16%78.99M
121.42%77.32M
93.93%34.92M
59.70%18.01M
32.65%11.28M
218.20%8.5M
--2.67M
----
----
Research and development costs
122.69%128.84M
69.49%57.86M
47.87%34.14M
9.09%23.09M
13.21%21.16M
527.87%18.69M
--2.98M
----
----
Depreciation amortization depletion
25.36%6.74M
3.96%5.38M
5.98%5.17M
15.25%4.88M
60,692.19%4.24M
83.71%6.97K
--3.79K
----
----
-Depreciation and amortization
25.36%6.74M
3.96%5.38M
5.98%5.17M
15.25%4.88M
60,692.19%4.24M
83.71%6.97K
--3.79K
----
----
Other operating expenses
-100.53%-173K
55.50%32.7M
299.30%21.03M
25.02%5.27M
5,725.42%4.21M
-91.70%72.32K
--871.01K
----
----
Operating profit
141.29%39.24M
3.83%-95.02M
-98.45%-98.8M
-23.67%-49.79M
-45.57%-40.26M
-323.94%-27.65M
-6.52M
Net non-operating interest income (expenses)
-90.57%-12.75M
-28.25%-6.69M
-370.94%-5.22M
52.03%-1.11M
-860.54%-2.31M
926.85%303.73K
29.58K
Non-operating interest income
101,800.00%1.02M
--1K
----
-31.63%67K
-70.55%98K
753.65%332.75K
--38.98K
----
----
Non-operating interest expense
104.74%13.14M
22.96%6.42M
344.09%5.22M
-51.20%1.18M
8,198.30%2.41M
208.67%29.02K
--9.4K
----
----
Total other finance cost
129.60%636K
--277K
----
----
----
----
----
----
----
Other net income (expenses)
-1,076.64%-30.14M
-86.90%3.09M
695.98%23.55M
-74.14%2.96M
-1.59%11.44M
10,224.64%11.63M
112.64K
Special income (charges)
---804K
----
----
----
----
----
----
----
----
-Less:Impairment of capital assets
--804K
----
----
----
----
----
----
----
----
Other non-operating income (expenses)
-1,050.58%-29.34M
-86.90%3.09M
695.98%23.55M
-74.14%2.96M
-1.59%11.44M
10,224.64%11.63M
--112.64K
----
----
Income before tax
103.13%3.09M
-22.57%-98.62M
-67.86%-80.47M
-54.02%-47.94M
-98.05%-31.12M
-146.41%-15.71M
-6.38M
-71.97%-497K
-289K
Income tax
-138.92%-2.12M
12,026.67%5.46M
101.48%45K
6.36%-3.05M
-72.76%-3.26M
-1.88M
0
-71.97%-497K
-289K
Earnings from equity interest net of tax
Net income
105.01%5.21M
-29.27%-104.08M
-79.36%-80.51M
-61.08%-44.89M
-101.50%-27.87M
-116.87%-13.83M
-6.38M
-71.97%-497K
-289K
Net income continuous operations
105.01%5.21M
-29.27%-104.08M
-79.36%-80.51M
-61.08%-44.89M
-101.50%-27.87M
-116.87%-13.83M
---6.38M
-71.97%-497K
---289K
Noncontrolling interests
Net income attributable to the company
105.01%5.21M
-29.27%-104.08M
-79.36%-80.51M
-61.08%-44.89M
-101.50%-27.87M
-116.87%-13.83M
-6.38M
-71.97%-497K
-289K
Preferred stock dividends
Other under preferred stock dividend
Net income attributable to common stockholders
105.01%5.21M
-29.27%-104.08M
-79.36%-80.51M
-61.08%-44.89M
-101.50%-27.87M
-116.87%-13.83M
-6.38M
-71.97%-497K
-289K
Diluted earnings per share
104.81%0.0161
-17.54%-0.335
-63.32%-0.285
-46.15%-0.1745
-74.56%-0.1194
-37.35%-0.0684
-0.0498
-72.00%-0.0129
-0.0075
Basic earnings per share
104.81%0.0161
-17.54%-0.335
-63.32%-0.285
-46.15%-0.1745
-74.56%-0.1194
-37.35%-0.0684
-0.0498
-72.00%-0.0129
-0.0075
Dividend per share
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
(FY)Dec 30, 2023(FY)Dec 30, 2022(FY)Dec 30, 2021(FY)Dec 30, 2020(FY)Dec 30, 2019(FY)Dec 30, 2018(FY)Dec 30, 2017(FY)Sep 30, 2000(FY)Sep 30, 1999
Total revenue 218.40%496.66M3,084.65%155.98M4.66%4.9M34.29%4.68M1,685.88%3.49M195.14K
Operating revenue 218.40%496.66M3,084.65%155.98M4.66%4.9M34.29%4.68M1,685.88%3.49M--195.14K------------
Cost of revenue 205.67%188.16M2,315.86%61.56M25.89%2.55M-20.41%2.02M2.54M
Gross profit 226.71%308.5M3,918.21%94.43M-11.52%2.35M181.95%2.66M382.73%942K195.14K
Operating expense 42.13%269.27M87.29%189.44M92.88%101.15M27.29%52.44M47.93%41.2M326.93%27.85M6.52M
Selling and administrative expenses 43.15%133.85M129.12%93.5M112.46%40.81M65.77%19.21M27.64%11.59M239.83%9.08M--2.67M--------
-Selling and marketing expense 238.96%54.87M174.78%16.19M390.10%5.89M285.26%1.2M-46.02%312K--577.95K------------
-General and administrative expense 2.16%78.99M121.42%77.32M93.93%34.92M59.70%18.01M32.65%11.28M218.20%8.5M--2.67M--------
Research and development costs 122.69%128.84M69.49%57.86M47.87%34.14M9.09%23.09M13.21%21.16M527.87%18.69M--2.98M--------
Depreciation amortization depletion 25.36%6.74M3.96%5.38M5.98%5.17M15.25%4.88M60,692.19%4.24M83.71%6.97K--3.79K--------
-Depreciation and amortization 25.36%6.74M3.96%5.38M5.98%5.17M15.25%4.88M60,692.19%4.24M83.71%6.97K--3.79K--------
Other operating expenses -100.53%-173K55.50%32.7M299.30%21.03M25.02%5.27M5,725.42%4.21M-91.70%72.32K--871.01K--------
Operating profit 141.29%39.24M3.83%-95.02M-98.45%-98.8M-23.67%-49.79M-45.57%-40.26M-323.94%-27.65M-6.52M
Net non-operating interest income (expenses) -90.57%-12.75M-28.25%-6.69M-370.94%-5.22M52.03%-1.11M-860.54%-2.31M926.85%303.73K29.58K
Non-operating interest income 101,800.00%1.02M--1K-----31.63%67K-70.55%98K753.65%332.75K--38.98K--------
Non-operating interest expense 104.74%13.14M22.96%6.42M344.09%5.22M-51.20%1.18M8,198.30%2.41M208.67%29.02K--9.4K--------
Total other finance cost 129.60%636K--277K----------------------------
Other net income (expenses) -1,076.64%-30.14M-86.90%3.09M695.98%23.55M-74.14%2.96M-1.59%11.44M10,224.64%11.63M112.64K
Special income (charges) ---804K--------------------------------
-Less:Impairment of capital assets --804K--------------------------------
Other non-operating income (expenses) -1,050.58%-29.34M-86.90%3.09M695.98%23.55M-74.14%2.96M-1.59%11.44M10,224.64%11.63M--112.64K--------
Income before tax 103.13%3.09M-22.57%-98.62M-67.86%-80.47M-54.02%-47.94M-98.05%-31.12M-146.41%-15.71M-6.38M-71.97%-497K-289K
Income tax -138.92%-2.12M12,026.67%5.46M101.48%45K6.36%-3.05M-72.76%-3.26M-1.88M0-71.97%-497K-289K
Earnings from equity interest net of tax
Net income 105.01%5.21M-29.27%-104.08M-79.36%-80.51M-61.08%-44.89M-101.50%-27.87M-116.87%-13.83M-6.38M-71.97%-497K-289K
Net income continuous operations 105.01%5.21M-29.27%-104.08M-79.36%-80.51M-61.08%-44.89M-101.50%-27.87M-116.87%-13.83M---6.38M-71.97%-497K---289K
Noncontrolling interests
Net income attributable to the company 105.01%5.21M-29.27%-104.08M-79.36%-80.51M-61.08%-44.89M-101.50%-27.87M-116.87%-13.83M-6.38M-71.97%-497K-289K
Preferred stock dividends
Other under preferred stock dividend
Net income attributable to common stockholders 105.01%5.21M-29.27%-104.08M-79.36%-80.51M-61.08%-44.89M-101.50%-27.87M-116.87%-13.83M-6.38M-71.97%-497K-289K
Diluted earnings per share 104.81%0.0161-17.54%-0.335-63.32%-0.285-46.15%-0.1745-74.56%-0.1194-37.35%-0.0684-0.0498-72.00%-0.0129-0.0075
Basic earnings per share 104.81%0.0161-17.54%-0.335-63.32%-0.285-46.15%-0.1745-74.56%-0.1194-37.35%-0.0684-0.0498-72.00%-0.0129-0.0075
Dividend per share
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Heat List
AU
Overall
Symbol
Price
% Chg

No Data

Investment Theme Healthcare - Cancer Research
Healthcare - Cancer Research
Intraday+0.01%